Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Peter M. Lynch, MPH
Advertisement
Articles by Peter M. Lynch, MPH
A retrospective claims analysis of managed care enrollees with type 2 diabetes mellitus showed that insulin pump therapy reduced antidiabetic drug and healthcare resource use.
Advertisement
Latest Updated Articles
Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative ClaimsPublished: April 3rd 2025 | Updated:
- Resource Utilization With Insulin Pump Therapy for Type 2 Diabetes Mellitus
Published: December 21st 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 Vaccination Linked to Lower Risk of Long COVID in Adolescents
2
Remote Monitoring May Improve Heart Failure Outcomes: Anitha Vijayan, MD
3
Breast Cancer Dominating Oncology Research, Access Disparities: Gen Li, PhD
4
Nearly All US Youth With BMI-Defined Obesity Have Excess Adiposity
5
